SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 277 filers reported holding SAGE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $276,000 | -48.8% | 3,200 | -83.0% | 0.23% | -20.3% |
| Q1 2020 | $539,000 | -89.4% | 18,800 | -32.6% | 0.29% | -19.2% |
| Q2 2019 | $5,108,000 | +248.7% | 27,900 | +82.4% | 0.35% | +250.5% |
| Q4 2018 | $1,465,000 | +48.3% | 15,300 | +118.6% | 0.10% | +77.2% |
| Q3 2018 | $988,000 | -77.3% | 7,000 | -90.0% | 0.06% | -75.5% |
| Q3 2017 | $4,354,000 | -21.8% | 69,900 | 0.0% | 0.23% | -32.1% |
| Q2 2017 | $5,566,000 | +36.2% | 69,900 | +21.6% | 0.34% | +32.9% |
| Q1 2017 | $4,086,000 | +1031.9% | 57,500 | +379.2% | 0.26% | +658.8% |
| Q2 2016 | $361,000 | -82.8% | 12,000 | -81.7% | 0.03% | -84.0% |
| Q1 2016 | $2,099,000 | +443.8% | 65,500 | +750.6% | 0.21% | +292.6% |
| Q1 2015 | $386,000 | +57.6% | 7,700 | +14.9% | 0.05% | +31.7% |
| Q4 2014 | $245,000 | – | 6,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |